Results 171 to 180 of about 77,471 (339)
Australian Practical Guide on the Management of Muscle‐Invasive Bladder Cancer
Asia-Pacific Journal of Clinical Oncology, EarlyView.Australia's management of muscle‐invasive bladder cancer is evolving, with increased use of perioperative therapy and emerging immunotherapies. However, challenges such as cisplatin ineligibility, limited access, and costs persist. Expanding bladder‐sparing approaches, precision medicine, and integrated care pathways will be key to improving outcomes ...
Dickon Hayne +6 more
wiley +1 more source
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
, 2006 The phosphatidylinositol 3-kinases (PI3K) are a family of enzymes that relay important cellular growth control signals. Recently, a large-scale mutational analysis of eight PI3K and eight PI3K-like genes revealed somatic mutations in PIK3CA, which ...
Siu, IM +27 more
core +1 more source
Acta Obstetricia et Gynecologica Scandinavica, EarlyView.This retrospective cohort compared umbilical‐portal‐systemic venous shunts in singleton and twin pregnancies. Type III was the most common subtype in singletons, whereas Type II was the most common in twins. Fetal growth restriction was more frequent in twins, but primary structural anomaly rates were similar.
Yun Zhang +8 more
wiley +1 more source
PI3K mutations in breast cancer: prognostic and therapeutic implications
Breast Cancer: Targets and Therapy, 2015 Toru MukoharaCancer Center and Division of Medical Oncology/Hematology, Kobe University Hospital, Kobe, JapanAbstract: The PI3K pathway is the most frequently enhanced oncogenic pathway in breast cancer.
Mukohara T
doaj
, 2015 BCS, breast conserving surgery; CMF, cyclophosphamide-methotrexate-5-fluorouracil; E, epirubicin; HR, hormone receptor; MAC, molecular apocrine; MRM, modified radical mastectomy; NR, not reported; PIK3CAhel, mutations present in the helical (and kinase ...
Chrisoula D. Scopa (439183) +23 more
core +1 more source
Brain Pathology, EarlyView.In a molecularly confirmed cohort of 64 newly diagnosed, TTFields‐treated glioblastomas, IDH‐wildtype, homozygous PTEN deletion was associated with markedly shorter overall survival (368 vs. 603 days) and remained an independent adverse prognostic factor.
Jakob Nückles +15 more
wiley +1 more source
New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer
Cancer Science, EarlyView.Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi +2 more
wiley +1 more source
The Journal of Liquid BiopsyPIK3CA mutations have been implicated in the prognosis and therapeutic response in HER2-positive early breast cancer, with variants located in exon 9 and exon 20 shown to modulate sensitivity to neoadjuvant chemotherapy.
Dimitra Stergiopoulou +7 more
doaj +1 more source
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
, 2015 Breast cancer is the most frequent cancer in women and consists of heterogeneous types of tumours that are classified into different histological and molecular subtypes.
Bouvencourt, Gaelle +27 more
core +1 more source
Cancer Science, EarlyView.In patients with esophageal squamous cell carcinoma receiving definitive radiotherapy combined with systemic therapy, posttreatment TP53 mutation clearance and ctDNA‐MRD negativity predict favorable outcomes, whereas persistent ctDNA signals indicate elevated relapse risk, supporting nucleosome‐ and MRD‐informed surveillance and risk‐stratification ...
Shutang Liu +9 more
wiley +1 more source